Louise R. Rodino-Klapac
President of Research & Development and Technical OperationsDr. Louise R. Rodino-Klapac, Ph.D. has been President of Research & Development and Technical Operations at Sarepta Therapeutics, Inc. since July 16, 2025. She was Head of Research and Development at Sarepta Therapeutics, Inc. since November 17, 2021 until July 2025. Dr. Rodino-Klapac is Director of Alliance for Regenerative Medicine. She was Executive Vice President and Chief Scientific Officer of Sarepta Therapeutics, Inc. since December 14, 2020 until July 2025. She was Senior Vice President of Gene Therapy at Sarepta Therapeutics, Inc. from March 2019 to December 14, 2020 and served as its Vice President of Gene Therapy unit since June 4, 2018 until March 2019. Renowned for her work in molecular genetics and gene therapy, Dr. Rodino-Klapac was Head of the laboratory for gene therapy research for muscular dystrophies at Nationwide Children’s Hospital prior to joining Sarepta. From July 2010 to June 2018, Dr. Rodino-Klapac was an Associate Professor, Department of Pediatrics, The Ohio State University College of Medicine and Principal Investigator, Center for Gene Therapy for The Research Institute at Nationwide Children's Hospital and a faculty Member of the Biomedical Sciences Graduate Program and Molecular, Cellular and Developmental Biology Graduate Programs, The Ohio State University College of Medicine. Dr. Rodino-Klapac also served as the Ruth L. Kirschstein F32 Post-doctoral Fellow, National Institutes of Health, The Research Institute at Nationwide Children's Hospital; and was a post-doctoral researcher, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital. In February 2017, Dr. Rodino-Klapac co-founded Myonexus Therapeutics, Inc., a clinical stage gene therapy biotech company focused on treatment of Limb girdle muscular dystrophy (LGMD). Dr. Rodino-Klapac serves as Acting Chief scientific officer of Myonexus and in early May 2018, Sarepta announced a collaboration with Myonexus to develop potentially transformative gene therapies to treat five distinct forms of LGMD. Dr. Rodino-Klapac is the recipient of numerous awards, including the Forty Under 40 Award by Columbus Business First and the Department of Pediatrics Outstanding Junior Faculty Award for Innovation. She’s the author of numerous publications, among them papers published in The New England Journal of Medicine, Annals of Neurology and Pediatric Neurology. Dr. Rodino-Klapac received her bachelor’s degree in biology from Kings College and a Ph.D. in molecular genetics from The Ohio State University. She is a current Board Member of the Association for Regenerative Medicine, as well as a Member of the American Society for Gene and Cell Therapy and the American Academy of Neurology.
Positions
- Company NameSarepta Therapeutics, Inc.Stock CodeSRPTPositionPresident of Research & Development and Technical OperationsColleagues
- IMIan Michael EstepanPresident & COO
- MKM. Kathleen Behrens WilseyIndependent Chairwoman
- RHRyan H. WongExecutive VP & CFO
- CLCristin L. RothfussExecutive VP, General Counsel & Company Secretary
- DSDouglas S. IngramAdvisor
- MEMichael E. SeverinoCEO & Director
- HWHans WigzellChairman of Corporate Strategy Board & Independent Non-Employee Director
- RJRichard Jon BarryIndependent Director
- DPDeirdre P. ConnellyIndependent Director
